NEWS

       

Endpoints (Subscription Required)  |   September 22, 2021

The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home

Scorpion Therapeutics was named as one of the 2021 Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.  

September 22, 2021

Scorpion Therapeutics Named to the 2021 Endpoints 11

BOSTON, MA. — September 22, 2021 — Scorpion Therapeutics was selected today as one of this year’s Endpoints 11, a group of the most promising up-and-coming...

STAT (Subscription Required)  |   July 9, 2021

Up and down the ladder: The latest comings and goings

Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...

Boston Business Journal  |   July 9, 2021

GSK’s head of oncology jumps to Boston precision medicine startup

Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...

Scrip (Subscription Required)  |   July 7, 2021

GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...

BioCentury (Subscription Required)  |   July 7, 2021

In GSK’s Hoos, Scorpion gains oncology pathfinder to match its $270M war chest

GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO...

July 7, 2021

Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.

BOSTON, MA. — July 7, 2021 — Scorpion Therapeutics, Inc., a next-generation oncology company developing best- and first-in-class precision medicines for cancer patients, today announced that...

Fierce Biotech  |   July 7, 2021

GSK oncology exec Hoos heads back to biotech as CEO of Scorpion Therapeutics

After leading oncology teams at GlaxoSmithKline and Bristol Myers Squibb, Axel Hoos, M.D., Ph.D., is heading back to biotech.  

Endpoints  |   July 7, 2021

Axel Hoos, the keeper of the oncology flame at GlaxoSmithKline, steps away for his next challenge at tiny Scorpion

Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and...

Boston, MA  |   April 8, 2021

Scorpion Therapeutics Appoints Guy Padbury, Ph.D. as Chief Development Officer

BOSTON, MA. — April 8, 2021 — Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the appointment of Guy Padbury, Ph.D. as Chief Development...